Navigation Links
Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Date:9/5/2013

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas.  The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting techniques; and (iii) First-in-man study findings of its trypsin-liable extended-release hydromorphone prodrug.

(Logo:  http://photos.prnewswire.com/prnh/20130729/SF54809LOGO)

Every year in the United States prescription opioid abuse is responsible for tens of thousands of deaths and tens of billions of dollars in increased health care costs.  Wes Sterman, President and CEO of Signature Therapeutics, commented, "We believe that our prodrug technology approach creating abuse-deterrent opioid drugs has the potential to greatly impact the public health crisis of prescription drug abuse."

About The Opioid Abuse Challenge

The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States. Despite efforts to develop opioid drug formulations that are resistant to tampering, abusers will soon match the advances in pill/tablet formulation technology with new ways to abuse these drugs.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.

About Signature Therapeutics

Signature Therapeutics, Inc. is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders.

Signature Therapeutics Contact:

Carey DeRafael

email: cderafael@signaturerx.com
phone: 650-331-4006
website: http://www.signaturerx.com



'/>"/>
SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Senator Shares Insight on Florida Physician Dispensing Legislation as First Guest of Progressive Medicals New SignatureSeries
2. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
3. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
4. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
Breaking Medicine News(10 mins):